These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31272958)

  • 21. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis.
    Chen J; Chen G; Sun H
    Hormones (Athens); 2021 Jun; 20(2):279-286. PubMed ID: 33783712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy.
    Ye X; Bo X; Hu X; Cui H; Lu B; Shao J; Wang J
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):247-255. PubMed ID: 27484048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.
    Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves' Orbitopathy.
    Oeverhaus M; Witteler T; Lax H; Esser J; Führer D; Eckstein A
    Horm Metab Res; 2017 Oct; 49(10):739-747. PubMed ID: 28922676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
    Sabini E; Sisti E; Coco B; Leo M; Ionni I; Menconi F; Profilo MA; Mazzi B; Rocchi R; Latrofa F; Vitti P; Brunetto M; Marcocci C; Marinò M
    J Endocrinol Invest; 2016 Nov; 39(11):1323-1327. PubMed ID: 27465669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic safety analysis of mycophenolate in Graves' orbitopathy.
    Lee ACH; Riedl M; Frommer L; Diana T; Kahaly GJ
    J Endocrinol Invest; 2020 Jun; 43(6):767-777. PubMed ID: 31834613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of moderate to severe orbitopathy: Current modalities and perspectives.
    Bouzehouane N; Borson-Chazot F; Abeillon J; Caron P
    Ann Endocrinol (Paris); 2021 Apr; 82(2):92-98. PubMed ID: 33676921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
    Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
    Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis.
    Fatani WA; Hamdan DM; Taher NO; Alsharef JF; Aldubi RM; Alwagdani AM; Alhothali TN; Khan ZU
    Saudi J Ophthalmol; 2023; 37(2):137-148. PubMed ID: 37492211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.
    Li HX; Xiang N; Hu WK; Jiao XL
    J Endocrinol Invest; 2016 Nov; 39(11):1225-1233. PubMed ID: 27220843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.
    Stiebel-Kalish H; Robenshtok E; Hasanreisoglu M; Ezrachi D; Shimon I; Leibovici L
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2708-16. PubMed ID: 19491222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves' orbitopathy?
    Bartalena L; Veronesi G; Krassas GE; Wiersinga WM; Marcocci C; Marinò M; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G; Perros P; Kahaly GJ;
    J Endocrinol Invest; 2017 May; 40(5):547-553. PubMed ID: 28176220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?
    Bartalena L
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):149-52. PubMed ID: 20148907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunosuppressive therapies in patients with Graves' ophthalmopathy].
    Wang J; Wang YT; Shao JQ; Wang X; Du H
    Zhonghua Nei Ke Za Zhi; 2004 Feb; 43(2):125-7. PubMed ID: 15059413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.